Member Info for Elsol

Agreed. If long covid positive data is a partial outcome from SNGs trials then its looking v. V. rosy....indeed.

Thanks Thorndon. Good searching my friend. Momentum building for sure...I like the following eco dishwasher customer review: Great product!
Review by Karen C. on 15 Jun 2022. review stating : "Great product as are all of 'Homethings'. Performs better than my previous eco wash liquid at a competitive price. I really like the fragrance free option as this has always been my preference but difficult to find. I am now getting this on subscription as will never go back to other supposedly eco products which produce so much plastic waste."

I saw some interesting patterns in my tea leaves today as most days! But joking aside its quite probable given all the prior announcements and facts surrounding SNG plus some minor background resurgent jitters on continuing Bxx.x variants arriving. One day the pesty microbes will become worrisome again its a matter of bio-self propagation and ticking clocks.

Share price up trend since April clearly tracking towards year end expected performance now. The share will also benefit from portfolio de-risking brought by new adds and increasing customer diversification. I think the pipeline looks very strong given JS comments at the webinar and not over playing it conservatively as expected. All looks great for next 12months and leverage from increased share access in USA

I also think the share aggregation is very accretive as it opens up a massive new US share buyer population which marries to ITX location and key customers and visibility there

All seems pretty good to me given the insightful forward looking statement from Jon. 50% CAGR. Cashflows are strong brand intensive and v. stable and defensive. So SP should easily grow at 50% pa same rate.

SNG001 has broad utility across viruses so it is a goer. Just have to wait until we get a near term catalyst event IMO

In the short to medium term SNG001 is a fantastic agnostic insurance policy for viral defence globally that's for sure (big economic downside protection policy) so I'm waiting patiently for the commercial and governmental traction to build...whether that's catalysed by ACTIV2 ++decisions and other freebie trials or interested parties wanting a licensing deal or a buy out..it will happen

This is worth more than 2GBP Per share IMV for this smaller target segment. The SP will be going up thankfully quite materially over a few days as this sinks in.....

Invisible to the naked eye, mutation creeps on; humans' heads in sand or in glasses of fridays favorite tipple,. Genetic evolution never sleeps, it's only a matter of time before another major viral breakthrough then panic again and more mask wearing shortages in shops..and vaccines left behind as pretty useless. Hope not but is that our future??

If we are expecting a catalyst announcement of a new supply agreement for example that drives the SP

If you expect a medium term re rate on the share price in 2022, then why burn and issue share values at lower price per share? Just wait then you get more cash per share by waiting. QED

Very investable rapidly growing business. Everyone will now see this. 12p target for year end with prospect for more if transformational order in new large market drops in

BA2 is now 34.9% in USA

A wise mentor once taught me (William!)—whenever you see exponential change—#BA2—it’s safe to assume among 3 things:

??Something new / different is driving it
??It must be either faster/better/stronger
??Something new will likely occur soon

Figure @DrWilliamKu #COVID19 https://t.co/iZAHc1UAfX

4) another worrisome thing is that reinfection % rate has also begun to recently spike in England ??????????????— coinciding with the surge in BA2 and cases— Especially worrisome since UK is surging after a recent BA1 Omicron wave. This is the stuff that I ponder at night why. https://t.co/0RtAod2fFm

Sorry can't seem to link it but I'm sure you will find it!

Is it not worth someone that's knowledgeable in the clinical trial stats world setting out a case that SNG should push for EUA in the US? Maybe through a well worded technical email to Brooke that tries to point out the triangulation of ALL the clinical evidence and in vitro data AND the science points in the same direction here and plus the safety observed too...what's the fecking chance that all of these observations happening by chance and are all saying the same? Can a mathematical genius write a proof statement that the chance of all of these occurrences are extremely unlikely unless SNG001 actually works well. An analogy (topic is unfavourable but bear with me for illustration purposes only!) ....It's crazy that we can observe a potential for a ballistic missile to travel 20miles into the atmosphere but not quite become weightless at 20.5miles high which is the marker for mathematical proof of success, but if you send up 3 or 4 up after each other and don't put enough fuel in them then they all go up to within a slight margin of reaching success at 20.5miles altitude. So, do you believe the ballistic missile is a failure??. No you just put some more gas in the tank next time. If it looks and smells like a missile, if it takes off like a missile and rises high at 1000mph like missile you probably have a missile that works....is the purist each isolated observation statistical measurement yardstick fecked up not the product????

Tommy. Thanks for all your informative posts. What I'm not getting at the moment is why the FDA works not consider all of the clinical data together from all the trials. You would see that this product is very safe. You would always see a baseline signal poking above the background noise but perhaps not in each discrete trial as being stat significant. But when you look at the patterns and correlations and work out the fluke chance of all the trials pointing to "it works" then that has to be highly highly significant. Eg. The sprinter intent to treat v's full protocol shows a partial response in the former. If 90% of the sprinter countries show positive response characteristics. Eg all the same direction. What is the chance of that happening by fluke given 2 completely other trials gave the same trend indication. I'm sure the broader maths stats and sheer improbability of no efficacy prove: 1 it's safe and 2 it works well enough to approve.

The reason I invested far too much here originally was my perceived downside value case (in the long run) that was going to be underpinned for the use of SNG001 against metabolic disorders of interferon production or presence of auto self antibodies for all manner respiratory infections that I believe are between 0.5% and 1% of an average population size. So it's just a hold for me now to see if that cones to fruition or partially via trade sale or out-licensing event. Ordinarily that may get you $1bn of value in the future but given value leakage on sale then £0.4 to £0.5bn is where I'm still minimum. If we get good activ and deep dive then I'm still optimistic its at least 2x that number in the long run, but such a painful wait again.

Cars- People can post anything they think is relevant without you being judgemental and a bully.

So David...., do you think an agnostic innate immune system enhancer could help out with this? ;-) yep!

Not necessarily so Bruce. Mutations are random in nature and can take viral severity up or down quite by chance, especially if they jump several mutation steps at once. Look at some of the worst influenza outbreaks during the last few hundred years...as one example. Are we saying flu will gradually disappear as a potentially harmful pathogen...nope. Guess again. We are already seeing vaccine infectious creep around for SARS cov2. Creeping mutations also create larger jumps that kick start a bad variant.